A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual...

Title

Code

CabOSTar

Type

Sperimentale con farmaco

Start Year

2024

Status

In Corso

Principal Investigator

051-6366102

toni.ibrahim@ior.it

Ibrahim Toni, BSc, MSc, MD, PhD

Director

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies

Operational unit that carry out the study

complex unit

Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative

Director

Ibrahim Toni, BSc, MSc, MD, PhD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. CabOSTar

Tuesday 25 June 2024, 17:01

PG0009972_2024_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

DIPARTIMENTO RIZZOLI-SICILIA

A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual...

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in